[go: up one dir, main page]

MX2024010030A - Formulaciones orales de fasudil con resina de intercambio ionico. - Google Patents

Formulaciones orales de fasudil con resina de intercambio ionico.

Info

Publication number
MX2024010030A
MX2024010030A MX2024010030A MX2024010030A MX2024010030A MX 2024010030 A MX2024010030 A MX 2024010030A MX 2024010030 A MX2024010030 A MX 2024010030A MX 2024010030 A MX2024010030 A MX 2024010030A MX 2024010030 A MX2024010030 A MX 2024010030A
Authority
MX
Mexico
Prior art keywords
ion exchange
exchange resin
composition
fasudil
dosage form
Prior art date
Application number
MX2024010030A
Other languages
English (en)
Inventor
Thomas Macallister
Qicai Liu
Hemant N Joshi
Original Assignee
Woolsey Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Woolsey Pharmaceuticals Inc filed Critical Woolsey Pharmaceuticals Inc
Publication of MX2024010030A publication Critical patent/MX2024010030A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

Se proporciona una composición farmacéutica oral que puede comprender un inhibidor de la rho quinasa, por ejemplo, fasudil, una sal farmacéuticamente aceptable de este, un hidrato de este, un profármaco de este, un derivado sustituido de este, o un metabolito de este, o cualquier combinación de estos, el inhibidor de la rho quinasa tiene sabor amargo; y una resina de intercambiio iónico. La resina de intercambio iónico puede enmascarar parcial o completamente el sabor amargo del inhibidor de la rho quinasa, haciendo que la composición sea más agradable. La composición puede comprender una forma de dosificación sólida, y/o una forma de dosificación líquida. La forma de dosificación sólida puede comprender un polvo, gránulos, un comprimido, o una cápsula, o cualquier combinación de estos. La composición puede estar presente, por ejemplo, en una dosis unitaria, en una cantidad suficiente para tratar una enfermedad neurodegenerativa. Se proporciona un método para tratar la enfermedad neurodegenerativa con la composición farmacéutica oral. El método puede mejorar un síntoma de una enfermedad neurodegenerativa.
MX2024010030A 2022-02-17 2023-02-17 Formulaciones orales de fasudil con resina de intercambio ionico. MX2024010030A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263311272P 2022-02-17 2022-02-17
PCT/US2023/013294 WO2023158789A1 (en) 2022-02-17 2023-02-17 Oral formulations of fasudil with ion exchange resin

Publications (1)

Publication Number Publication Date
MX2024010030A true MX2024010030A (es) 2024-09-24

Family

ID=87578887

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010030A MX2024010030A (es) 2022-02-17 2023-02-17 Formulaciones orales de fasudil con resina de intercambio ionico.

Country Status (7)

Country Link
US (3) US20250134906A1 (es)
EP (1) EP4479058A1 (es)
JP (1) JP2025506684A (es)
CN (1) CN118922193A (es)
CA (1) CA3243912A1 (es)
MX (1) MX2024010030A (es)
WO (1) WO2023158789A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230405017A1 (en) * 2020-03-25 2023-12-21 Woolsey Pharmaceuticals, Inc. Methods of using rho kinase inhibitors to treat frontotemporal dementia
WO2023158787A1 (en) 2022-02-17 2023-08-24 Woolsey Pharmaceuticals, Inc. Taste-masking oral formulations of fasudil
WO2024238620A1 (en) * 2023-05-17 2024-11-21 Woolsey Pharmaceuticals, Inc. Methods of treating traumatic encephalopathy syndrome
WO2025171484A1 (en) * 2024-02-15 2025-08-21 Raya Therapeutic Inc. Sublingual compositions for fasudil

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678783B1 (en) 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
JP3464012B2 (ja) * 1993-04-05 2003-11-05 旭化成株式会社 精神症候治療剤
EP0870767B1 (en) 1995-07-03 2000-02-16 Asahi Kasei Kogyo Kabushiki Kaisha 1-(5-isoquinolinesulfonyl)homopiperazine hydrochloride hydrates
US5980882A (en) * 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
KR100396171B1 (ko) 1998-08-10 2003-08-27 아사히 가세이 가부시키가이샤 염산 파수딜의 경구 서방성 제제
WO2002079778A2 (en) * 2001-03-28 2002-10-10 Rheologics, Inc. In vivo delivery methods and compositions
CN1929847B (zh) 2004-03-16 2011-01-19 旭化成制药株式会社 含有法舒地尔的制剂及改善其稳定性的方法
WO2005117896A1 (de) 2004-06-03 2005-12-15 Schering Aktiengesellschaft Formulierungen, die fasudil, eine matrix und einem mantel enthalten
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US7893050B2 (en) * 2005-10-26 2011-02-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
CN100367967C (zh) 2005-12-12 2008-02-13 天津红日药业股份有限公司 一种盐酸法舒地尔口服制剂
CN101092413B (zh) 2006-06-23 2011-05-18 山东轩竹医药科技有限公司 法舒地尔的药用盐的水合物
US8568785B2 (en) 2006-07-19 2013-10-29 Asahi Kasei Chemicals Corporation Process for producing spherical base granule comprising easily water-soluble drug
CN102008487A (zh) 2010-11-12 2011-04-13 天津红日药业股份有限公司 法舒地尔经雾化吸入用于制备治疗肺动脉高压药物中的应用
US9339478B2 (en) * 2011-02-04 2016-05-17 Reckitt Benckiser Llc Pharmaceutical formulation
CN102144971B (zh) 2011-03-30 2012-10-03 天津红日药业股份有限公司 一种含法舒地尔的口腔喷雾剂或气雾剂
DK2825175T3 (da) 2012-03-12 2017-11-06 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin Rho-kinase-inhibitorer til anvendelse i behandling af amyotrofisk lateral sklerose
CN102772381B (zh) 2012-07-30 2014-01-15 天津红日药业股份有限公司 一种含有法舒地尔的药物组合物
EP3943072A1 (en) 2015-07-27 2022-01-26 Sun Pharma Advanced Research Company Ltd Drug loaded nanoresin particles
EP3868408A4 (en) * 2018-10-15 2022-07-06 National University Corporation Tokai National Higher Education and Research System Antipsychotic and use thereof
US11612566B2 (en) 2019-05-29 2023-03-28 OWP Pharmaceuticals, Inc. Lamotrigine oral liquid suspension and use thereof
AU2020302092A1 (en) 2019-06-28 2022-01-27 Chdi Foundation, Inc. Rho kinase inhibitors and compositions and methods of use thereof
WO2023158787A1 (en) 2022-02-17 2023-08-24 Woolsey Pharmaceuticals, Inc. Taste-masking oral formulations of fasudil

Also Published As

Publication number Publication date
CN118922193A (zh) 2024-11-08
US20250134906A1 (en) 2025-05-01
EP4479058A1 (en) 2024-12-25
US12115167B2 (en) 2024-10-15
US20230330101A1 (en) 2023-10-19
WO2023158789A1 (en) 2023-08-24
US11944633B2 (en) 2024-04-02
JP2025506684A (ja) 2025-03-13
US20240269147A1 (en) 2024-08-15
CA3243912A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
MX2024010030A (es) Formulaciones orales de fasudil con resina de intercambio ionico.
JP5554069B2 (ja) ビタミンおよびミネラル補助食品における改善された安定性
KR102226833B1 (ko) 레보세티리진 및 몬테루카스트를 포함하는 안정성이 개선된 복합 과립 제형
FI2508188T3 (fi) Dapagliflotsiinipropyleeniglykolihydraattia sisältäviä farmaseuttisia formulaatioita
WO2009102038A1 (ja) 口腔内崩壊錠
JP6803250B2 (ja) エレトリプタン臭化水素酸塩含有口腔内崩壊錠
JP2021017445A (ja) フェキソフェナジンを含有する医薬組成物
WO2015007890A1 (en) Pharmaceutical combinations of pregabalin
JP2004269513A (ja) 固形製剤
KR102631399B1 (ko) 폴마콕시브 및 프레가발린을 포함하는 통증 치료용 약제학적 조성물
JP2020203874A (ja) ロキソプロフェン又はその塩とカノコソウとを含有する経口用医薬組成物
HRP20231170T1 (hr) Proces za proizvodnju tableta jednostavnih za uzimanje sa suhim ekstraktom iz listova ginko bilobe
CN115666516A (zh) 包括卡培他滨的快速分散药物组合物
KR102903389B1 (ko) 신경퇴행성 질환 예방 또는 치료용 필름코팅정제
KR20210153044A (ko) 의존성 치료를 위한 식물 알칼로이드를 포함하는 경구 약제학적 조성물
JP2016216371A (ja) ロスバスタチン含有口腔内速崩壊錠
AU2015101120A4 (en) Formulation for oral administration
ES2365961B1 (es) Formulación farmacéutica a base de ibuprofeno y codeína de estabilidad mejorada.
CN103860532A (zh) 美金刚和二甲双胍的复方药用组合物及其制备方法
TWI430807B (zh) 協同性地增高消化管運動賦活作用之胃腸藥組成物
TWI781925B (zh) 經口服途徑投予的γ-羥丁酸（ＧＨＢ）或其治療上可接受的鹽中之一者之用途
JP6304751B2 (ja) ワルファリン含有固形製剤及びその製造方法
JP7368097B2 (ja) ロキソプロフェン又はその塩とタウリンとを含有する経口医薬組成物
JP6878021B2 (ja) トリプタンとアスコルビン酸を含有する医薬組成物
Gupta et al. True MDTS: Mouth disintegrating tablets or mouth dissolving tablets, a comparative study